Ticker > Company >

Zenotech Laboratorie share price

Zenotech Laboratories Ltd.

BSE: 532039 SECTOR: Pharmaceuticals & Drugs  25.53 K   72   3

55.18
-0.44 (-0.79%)
BSE: Today, 10:13 AM

Price Summary

Today's High

₹ 55.2

Today's Low

₹ 54

52 Week High

₹ 104.8

52 Week Low

₹ 51

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

336.77 Cr.

Enterprise Value

317.08 Cr.

No. of Shares

6.1 Cr.

P/E

64.02

P/B

3.47

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  15.91

CASH

19.69 Cr.

DEBT

0 Cr.

Promoter Holding

68.84 %

EPS (TTM)

₹  0.86

Sales Growth

-3.75%

ROE

9.6 %

ROCE

12.89%

Profit Growth

-28.37 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-3.75%
3 Year22.08%
5 Year25.67%

Profit Growth

1 Year-28.37%
3 Year106.69%
5 Year36.01%

ROE%

1 Year9.6%
3 Year20.67%
5 Year16.78%

ROCE %

1 Year12.89%
3 Year15.52%
5 Year13.07%

Debt/Equity

0

Price to Cash Flow

28.48

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

1.30321004682085

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 68.84 0.00
Mar 2025 68.84 0.00
Dec 2024 68.84 0.00
Sep 2024 68.84 0.00
Jun 2024 68.84 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 22.0755692007782% for the Past 3 years.
  • Company has been maintaining healthy ROE of 20.6708996332301% over the past 3 years.
  • Company is virtually debt free.
  • The Company has been maintaining an effective average operating margins of 40.3331831683494% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 36.8874 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.30321004682085.
  • The company has a high promoter holding of 68.84%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 19.9573041877793.

 Limitations

  • The company is trading at a high PE of 64.02.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 9.91 9.76 11.24 12.13 9.64
Total Expenditure 6.48 7.36 7.37 7.66 7.18
Operating Profit 3.44 2.41 3.87 4.47 2.46
Other Income 0.34 0.34 0.37 0.49 0.59
Interest 0 0 0 0 0
Depreciation 1.73 1.75 1.76 1.73 1.77
Exceptional Items 0 1.35 0.62 -0.05 0
Profit Before Tax 2.05 2.35 3.11 3.19 1.28
Tax 0.76 1 1.42 1.96 0.29
Profit After Tax 1.29 1.35 1.69 1.23 0.99
Adjusted EPS (Rs) 0.21 0.22 0.28 0.2 0.16

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 26.02 22.45 36.57 42.42 40.83
Total Expenditure 17.04 16.07 19.1 21.72 23.61
Operating Profit 8.98 6.38 17.46 20.7 17.22
Other Income 1.17 0.41 0.63 1.08 1
Interest 0.89 1.55 1.22 0.11 0
Depreciation 4.85 6.46 6.97 7.17 7.09
Exceptional Items 6.37 0 0 0 0
Profit Before Tax 10.78 -1.22 9.9 14.5 11.14
Tax 0 0 -12.27 2.92 2.84
Net Profit 10.78 -1.22 22.18 11.59 8.3
Adjusted EPS (Rs.) 1.77 -0.2 3.63 1.9 1.36

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 61.03 61.03 61.03 61.03 61.03
Total Reserves -11.4 -12.62 9.61 21.24 29.51
Borrowings 0 20.66 6 0 0
Other N/C liabilities 0.49 1.83 -10.41 -7.36 -4.38
Current liabilities 35.44 14.95 15.58 16.61 13.52
Total Liabilities 85.55 85.84 81.81 91.52 99.68
Assets
Net Block 48.73 74.23 70.91 65.38 65.58
Capital WIP 29.08 2.18 0.28 4.98 1.96
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 1.94 1.98 3.15 4.79 5.75
Other N/C Assets 0.1 0.1 0.1 0.1 0.23
Current Assets 5.71 7.35 7.37 16.26 26.16
Total Assets 85.55 85.84 81.81 91.52 99.68
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 10.78 -1.22 9.9 14.5 11.14
Adjustment -1.68 7.66 8.01 6.86 6.17
Changes in Assets & Liabilities 2.56 -0.59 0.76 0.49 -4.41
Tax Paid -0.28 -0.12 -1 -1.19 -1.07
Operating Cash Flow 11.38 5.74 17.67 20.66 11.82
Investing Cash Flow -20.79 -4.82 -1.84 -5.82 -21.15
Financing Cash Flow -2.7 0.45 -15.87 -6.11 0
Net Cash Flow -12.11 1.38 -0.04 8.73 -9.33

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 68.84 68.84 68.84 68.84 68.84
sun pharmaceutical indust... 68.84 68.84 68.84 68.84 68.84
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 31.16 31.16 31.16 31.16 31.16
dr. jayaram chigurupati 3.59 3.59 3.59 3.59 3.59
minal bharat patel 1.99 1.99 1.77 1.72 1.72
padmasree chigurupati 5.26 5.26 5.26 5.26 5.26
pat financial consultants... 3.98 3.98 3.98 3.98 3.98
zenotech llc 1.14 1.14 1.14 1.14 1.14

Annual Reports

Title Link
Title Link
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Zenotech Laboratories informs about newspaper publication 30 Jul, 11:03 AM Zenotech Laboratorie - Quaterly Results 28 Jul, 7:04 PM Zenotech Laboratorie - Quaterly Results 28 Jul, 7:04 PM Zenotech Laboratories informs about board meeting 19 Jul, 11:19 AM Zenotech Laboratories informs about integrated filing 26 Apr, 4:21 PM Zenotech Laboratorie - Quaterly Results 25 Apr, 6:22 PM Zenotech Laboratorie - Quaterly Results 25 Apr, 6:22 PM Zenotech Laboratorie - Quaterly Results 25 Apr, 6:22 PM Zenotech Laboratories informs about integrated financial filing 15 Feb, 4:18 PM Zenotech Laboratories informs about newspaper advertisement 30 Jan, 10:21 AM Zenotech Laboratorie - Quaterly Results 28 Jan, 3:32 PM Zenotech Laboratorie - Quaterly Results 28 Jan, 3:32 PM Zenotech Laboratorie - Quaterly Results 28 Jan, 3:32 PM Zenotech Laboratories informs about closure of trading window 27 Dec, 10:31 AM Zenotech Laboratories informs about outcome of board meeting 23 Oct, 4:22 PM Zenotech Laboratorie - Quaterly Results 23 Oct, 3:03 PM Zenotech Laboratorie - Quaterly Results 23 Oct, 3:03 PM Zenotech Laboratorie - Quaterly Results 23 Oct, 3:03 PM Zenotech Laboratories informs about press release 3 Sep, 5:24 PM Zenotech Laboratorie - Quaterly Results 26 Jul, 5:31 PM Zenotech Laboratorie - Quaterly Results 26 Jul, 5:31 PM Zenotech Laboratorie - Quaterly Results 26 Jul, 5:31 PM Zenotech Laboratories informs about newspaper advertisement 3 May, 10:54 AM Zenotech Laboratorie - Quaterly Results 1 May, 8:18 PM Zenotech Laboratorie - Quaterly Results 1 May, 8:18 PM Zenotech Laboratorie - Quaterly Results 29 Jan, 6:39 PM Zenotech Laboratorie - Quaterly Results 29 Jan, 6:39 PM Zenotech Laboratorie - Quaterly Results 29 Jan, 6:39 PM Zenotech Laboratorie - Quaterly Results 30 Oct, 7:00 PM Zenotech Laboratorie - Quaterly Results 30 Oct, 7:00 PM Zenotech Laboratories informs about compliances-certificate 12 Oct, 4:55 PM Zenotech Laboratories informs about press release 6 Sep, 2:05 PM Zenotech Laboratories informs about newspaper publication 2 Sep, 1:01 PM Zenotech Laboratorie - Quaterly Results 1 Aug, 7:48 PM Zenotech Laboratorie - Quaterly Results 1 Aug, 7:48 PM Zenotech Laboratories informs about non-applicability of large corporate entity 3 May, 12:16 PM Zenotech Laboratorie - Quaterly Results 28 Apr, 8:16 PM Zenotech Laboratorie - Quaterly Results 28 Apr, 8:16 PM Zenotech Laboratorie - Quaterly Results 27 Jan, 7:28 PM Zenotech Laboratorie - Quaterly Results 27 Jan, 7:28 PM Zenotech Laboratories informs about compliances-certificate 10 Jan, 5:42 PM Zenotech Laboratorie - Quaterly Results 28 Oct, 7:16 PM Zenotech Laboratorie - Quaterly Results 28 Oct, 7:16 PM Zenotech Laboratories informs about board meeting 20 Oct, 10:19 AM Zenotech Laboratories informs about closure of trading window 26 Sep, 1:01 PM Zenotech Laboratories informs about newspaper advertisements 29 Aug, 12:34 PM Zenotech Laboratories informs about 33rd AGM 27 Aug, 4:35 PM Zenotech Laboratorie - Quaterly Results 22 Jul, 6:50 PM Zenotech Laboratorie - Quaterly Results 22 Jul, 6:50 PM Zenotech Laboratories informs about board meeting 14 Jul, 10:53 AM

Zenotech Laboratorie Stock Price Analysis and Quick Research Report. Is Zenotech Laboratorie an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Zenotech Laboratorie. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Zenotech Laboratorie has a PE ratio of 63.8125072514213 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Zenotech Laboratorie has ROA of 8.6808% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Zenotech Laboratorie has a Current ratio of 1.9347.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Zenotech Laboratorie has a ROE of 9.6043%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Zenotech Laboratorie has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Zenotech Laboratorie has reported revenue growth of -3.7507% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Zenotech Laboratorie for the current financial year is 42.1777920363627%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Zenotech Laboratorie is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Zenotech Laboratorie is Rs 0.8619. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Zenotech Laboratorie in Ticker for free. Also, one can get the intrinsic value of Zenotech Laboratorie by using Valuation Calculators, which are available with a Finology ONE subscription. 

Zenotech Laboratorie FAQs

Q1. What is Zenotech Laboratorie share price today?
Ans: The current share price of Zenotech Laboratorie is Rs 55.

Q2. What is the market capitalisation of Zenotech Laboratorie?
Ans: Zenotech Laboratorie has a market capitalisation of Rs 335.668124 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Zenotech Laboratorie?
Ans: The PE ratio of Zenotech Laboratorie is 63.8125072514213 and the P/B ratio of Zenotech Laboratorie is 3.45622843784759, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Zenotech Laboratorie share?
Ans: The 52-week high share price of Zenotech Laboratorie is Rs 104.8, and the 52-week low share price of Zenotech Laboratorie is Rs 51.

Q5. Does Zenotech Laboratorie pay dividends?
Ans: Currently, Zenotech Laboratorie does not pay dividends. Dividend yield of Zenotech Laboratorie is around 0%.

Q6. What are the face value and book value of Zenotech Laboratorie shares?
Ans: The face value of Zenotech Laboratorie shares is Rs 10, while the book value per share of Zenotech Laboratorie is around Rs 15.9133. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Zenotech Laboratorie?
Ans: Zenotech Laboratorie has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Zenotech Laboratorie?
Ans: The ROE of Zenotech Laboratorie is 9.6043% and ROCE of Zenotech Laboratorie is 12.8943%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Zenotech Laboratorie a good buy for the long term?
Ans: The Zenotech Laboratorie long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Zenotech Laboratorie undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Zenotech Laboratorie appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Zenotech Laboratorie’s financials?
Ans: You can review Zenotech Laboratorie’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Zenotech Laboratorie
X